Impact of intravitreal ranibizumab on vessel functionality in patients with retinal vein occlusion

Federico Corvi, Carlo La Spina, Lucia Benatti, Lea Querques, Rosangela Lattanzio, Francesco Bandello, Giuseppe Querques

Research output: Contribution to journalArticle

Abstract

Purpose To investigate the short-term effects of intravitreal ranibizumab on retinal vessel functionality in patients with retinal vein occlusion (RVO). Design Prospective, interventional case series. Methods We enrolled 11 eyes of 11 consecutive treatment-naïve patients with macular edema secondary to RVO. All patients underwent a complete ophthalmic evaluation, including optical coherence tomography and dynamic and static retinal vessel analysis, using the Dynamic Vessel Analyzer (Imedos, Jena, Germany) before (baseline) and 1 week and 1 month after administration of intravitreal ranibizumab. Investigations of RVO patients were compared to 11 eyes of age- and sex-matched control subjects. Results In RVO patients, dynamic analysis showed a significant increase of mean venous dilation from +2.46% ± 1.03% at baseline to +3.96% ± 1.3% at 1 week (P =.001). At 1 week mean maximum venous and arterial dilations did not differ from those of control subjects. Static analysis showed a mean overall significant decrease of central retinal artery equivalent and central retinal vein equivalent from baseline to 1 week (from 174.8 ± 22.5 measurement units [MU] to 167.2 ± 26.7 MU [P =.04], and from 228.4 ± 20.7 MU to 217.3 ± 22.8 [P =.0002]). Mean central retinal artery equivalent in healthy control subjects was 175.9 ± 10.45 MU, not significantly different from baseline, week 1, and month 1 of RVO eyes. Conversely, mean central retinal vein equivalent was 195.5 ± 9.91 MU in healthy control subjects, significantly different from baseline, week 1, and month 1 of RVO eyes. Conclusions Using the Dynamic Vessel Analyzer in patients with RVO, we found that intravitreal ranibizumab increased vein dilation (dynamic analysis) and had a vasoconstrictive effect on both arteries and veins (static analysis).

Original languageEnglish
Pages (from-to)45-52.e1
JournalAmerican Journal of Ophthalmology
Volume160
Issue number1
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Retinal Vein Occlusion
Retinal Artery
Retinal Vein
Dilatation
Retinal Vessels
Veins
Healthy Volunteers
Macular Edema
Optical Coherence Tomography
Ranibizumab
Germany
Arteries

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Impact of intravitreal ranibizumab on vessel functionality in patients with retinal vein occlusion. / Corvi, Federico; La Spina, Carlo; Benatti, Lucia; Querques, Lea; Lattanzio, Rosangela; Bandello, Francesco; Querques, Giuseppe.

In: American Journal of Ophthalmology, Vol. 160, No. 1, 01.07.2015, p. 45-52.e1.

Research output: Contribution to journalArticle

Corvi, Federico ; La Spina, Carlo ; Benatti, Lucia ; Querques, Lea ; Lattanzio, Rosangela ; Bandello, Francesco ; Querques, Giuseppe. / Impact of intravitreal ranibizumab on vessel functionality in patients with retinal vein occlusion. In: American Journal of Ophthalmology. 2015 ; Vol. 160, No. 1. pp. 45-52.e1.
@article{d8c7c78069ba4accb028f9dee54660d4,
title = "Impact of intravitreal ranibizumab on vessel functionality in patients with retinal vein occlusion",
abstract = "Purpose To investigate the short-term effects of intravitreal ranibizumab on retinal vessel functionality in patients with retinal vein occlusion (RVO). Design Prospective, interventional case series. Methods We enrolled 11 eyes of 11 consecutive treatment-na{\"i}ve patients with macular edema secondary to RVO. All patients underwent a complete ophthalmic evaluation, including optical coherence tomography and dynamic and static retinal vessel analysis, using the Dynamic Vessel Analyzer (Imedos, Jena, Germany) before (baseline) and 1 week and 1 month after administration of intravitreal ranibizumab. Investigations of RVO patients were compared to 11 eyes of age- and sex-matched control subjects. Results In RVO patients, dynamic analysis showed a significant increase of mean venous dilation from +2.46{\%} ± 1.03{\%} at baseline to +3.96{\%} ± 1.3{\%} at 1 week (P =.001). At 1 week mean maximum venous and arterial dilations did not differ from those of control subjects. Static analysis showed a mean overall significant decrease of central retinal artery equivalent and central retinal vein equivalent from baseline to 1 week (from 174.8 ± 22.5 measurement units [MU] to 167.2 ± 26.7 MU [P =.04], and from 228.4 ± 20.7 MU to 217.3 ± 22.8 [P =.0002]). Mean central retinal artery equivalent in healthy control subjects was 175.9 ± 10.45 MU, not significantly different from baseline, week 1, and month 1 of RVO eyes. Conversely, mean central retinal vein equivalent was 195.5 ± 9.91 MU in healthy control subjects, significantly different from baseline, week 1, and month 1 of RVO eyes. Conclusions Using the Dynamic Vessel Analyzer in patients with RVO, we found that intravitreal ranibizumab increased vein dilation (dynamic analysis) and had a vasoconstrictive effect on both arteries and veins (static analysis).",
author = "Federico Corvi and {La Spina}, Carlo and Lucia Benatti and Lea Querques and Rosangela Lattanzio and Francesco Bandello and Giuseppe Querques",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.ajo.2015.04.019",
language = "English",
volume = "160",
pages = "45--52.e1",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Impact of intravitreal ranibizumab on vessel functionality in patients with retinal vein occlusion

AU - Corvi, Federico

AU - La Spina, Carlo

AU - Benatti, Lucia

AU - Querques, Lea

AU - Lattanzio, Rosangela

AU - Bandello, Francesco

AU - Querques, Giuseppe

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose To investigate the short-term effects of intravitreal ranibizumab on retinal vessel functionality in patients with retinal vein occlusion (RVO). Design Prospective, interventional case series. Methods We enrolled 11 eyes of 11 consecutive treatment-naïve patients with macular edema secondary to RVO. All patients underwent a complete ophthalmic evaluation, including optical coherence tomography and dynamic and static retinal vessel analysis, using the Dynamic Vessel Analyzer (Imedos, Jena, Germany) before (baseline) and 1 week and 1 month after administration of intravitreal ranibizumab. Investigations of RVO patients were compared to 11 eyes of age- and sex-matched control subjects. Results In RVO patients, dynamic analysis showed a significant increase of mean venous dilation from +2.46% ± 1.03% at baseline to +3.96% ± 1.3% at 1 week (P =.001). At 1 week mean maximum venous and arterial dilations did not differ from those of control subjects. Static analysis showed a mean overall significant decrease of central retinal artery equivalent and central retinal vein equivalent from baseline to 1 week (from 174.8 ± 22.5 measurement units [MU] to 167.2 ± 26.7 MU [P =.04], and from 228.4 ± 20.7 MU to 217.3 ± 22.8 [P =.0002]). Mean central retinal artery equivalent in healthy control subjects was 175.9 ± 10.45 MU, not significantly different from baseline, week 1, and month 1 of RVO eyes. Conversely, mean central retinal vein equivalent was 195.5 ± 9.91 MU in healthy control subjects, significantly different from baseline, week 1, and month 1 of RVO eyes. Conclusions Using the Dynamic Vessel Analyzer in patients with RVO, we found that intravitreal ranibizumab increased vein dilation (dynamic analysis) and had a vasoconstrictive effect on both arteries and veins (static analysis).

AB - Purpose To investigate the short-term effects of intravitreal ranibizumab on retinal vessel functionality in patients with retinal vein occlusion (RVO). Design Prospective, interventional case series. Methods We enrolled 11 eyes of 11 consecutive treatment-naïve patients with macular edema secondary to RVO. All patients underwent a complete ophthalmic evaluation, including optical coherence tomography and dynamic and static retinal vessel analysis, using the Dynamic Vessel Analyzer (Imedos, Jena, Germany) before (baseline) and 1 week and 1 month after administration of intravitreal ranibizumab. Investigations of RVO patients were compared to 11 eyes of age- and sex-matched control subjects. Results In RVO patients, dynamic analysis showed a significant increase of mean venous dilation from +2.46% ± 1.03% at baseline to +3.96% ± 1.3% at 1 week (P =.001). At 1 week mean maximum venous and arterial dilations did not differ from those of control subjects. Static analysis showed a mean overall significant decrease of central retinal artery equivalent and central retinal vein equivalent from baseline to 1 week (from 174.8 ± 22.5 measurement units [MU] to 167.2 ± 26.7 MU [P =.04], and from 228.4 ± 20.7 MU to 217.3 ± 22.8 [P =.0002]). Mean central retinal artery equivalent in healthy control subjects was 175.9 ± 10.45 MU, not significantly different from baseline, week 1, and month 1 of RVO eyes. Conversely, mean central retinal vein equivalent was 195.5 ± 9.91 MU in healthy control subjects, significantly different from baseline, week 1, and month 1 of RVO eyes. Conclusions Using the Dynamic Vessel Analyzer in patients with RVO, we found that intravitreal ranibizumab increased vein dilation (dynamic analysis) and had a vasoconstrictive effect on both arteries and veins (static analysis).

UR - http://www.scopus.com/inward/record.url?scp=84930759809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930759809&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2015.04.019

DO - 10.1016/j.ajo.2015.04.019

M3 - Article

AN - SCOPUS:84930759809

VL - 160

SP - 45-52.e1

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -